Autobio Diagnostics (SHA:603658) said it obtained medical device registration certificates from China's National Medical Products Administration for three diagnostic kits, according to a Friday filing with the Shanghai Bourse.
The kits include an HER-2/neu test for breast cancer monitoring, a Group B Streptococcus DNA test for pregnant women, and an H. pylori IgG antibody test.
The approvals expand Autobio's product portfolio and enhance market competitiveness.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.